Belrose Pharma Launched to Develop Innovative Therapeutics for Diseases with High Unmet Medical Needs
New Specialty Pharmaceutical Company to Drive Development in Sustained Drug Release Products
Princeton, NJ, June 18, 2013 — Belrose Pharma Inc., a new specialty pharmaceutical company, was launched today to address opportunities to advance development of the next generation of innovative injectable and sustained release drug therapies in diseases with high unmet medical needs.
Belrose Pharma will focus on driving development of biologic, peptide, and small molecule-based therapies leveraging formulation and delivery technologies across a range of products, with a primary focus on oncology, immunology, antiviral, and orphan drug indications.
“Identifying new approaches to deliver therapies that are effective for patients with rare or life-threatening diseases is a top healthcare priority today and will continue to dominate clinical and caregiving resources in the years ahead,” said Belrose Pharma founder and CEO, Eric Gilbert. “We believe a development focus on breakthrough biologic and small molecule-based therapeutics enhanced and enabled by delivery technologies shows the greatest potential for providing a new level of effectiveness to patients with a range of rare or life-threatening diseases. We are committed to driving clinical, health and cost outcome breakthroughs in this area using Belrose’s formulation and delivery technologies,” added Gilbert.
Belrose Pharma will focus its business in two areas: advancing development of clinical and preclinical compounds in the Belrose pipeline, and product development for third-party customers pairing Belrose’s delivery technologies with molecules selected or previously developed by customers. To maximize the number of development activities that it can pursue simultaneously, Belrose has established strategic relationships with GMP manufacturing facilities with biologic and high potency capabilities, and plans to strategically employ candidate-specific investment vehicles to accelerate the progress of internal clinical programs.
About Belrose Pharma Inc.
Belrose Pharma Inc. (Princeton, NJ) is a specialty pharmaceutical company with two related businesses: (a) advancing development of internal clinical and pre-clinical compounds, and (b) product development for third party customers seeking to improve both early clinical and mid-lifecycle products using formulation and delivery technologies within its technology portfolio. Further information about Belrose can be found on the Company’s website at www.belrosepharma.com.
Press Enquiries: email firstname.lastname@example.org